Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 1466

Sort by

Sort Order Select

Journal Articles

GVHD in the era of checkpoint inhibition in Hodgkin lymphoma

Cecilia Anna Fidanza, Fabio Serpenti, Francesca Cavallaro, Kordelia Barbullushi, Nicolò Rampi, Francesca Gaia Rossi Dardanoni, Maria Goldaniga, Giorgia Natascia Saporiti, Francesco Passamonti

Blood Adv (2025) 9 (9): 2341–2343.

https://doi.org/10.1182/bloodadvances.2025015912

Published: 2025

Journal Articles

Molecular profiling of primary renal Marginal Zone Lymphoma reveals overlapping features with extranodal Marginal Zone Lymphoma

Axel Künstner, Vera von Kopylow, Philipp Lohneis, Matthias Kümmel, Hanno M. Witte, Dr, Veronica Bernard, Dr, Stephanie Stölting, Kathrin Kusch, Sivahari Prasad Gorantla, Manuela Krokowski, Nikolas von Bubnoff, Hartmut Merz, Prof, Hauke Busch, Alfred C. Feller, Niklas Gebauer

Blood Adv bloodadvances.2025016263.

https://doi.org/10.1182/bloodadvances.2025016263

Published: 2025

Includes: Supplemental data

Journal Articles

Dysregulated immune proteins in plasma in the UK Biobank predict Multiple Myeloma 12 years before clinical diagnosis

Joshua Fieggen, Anshul Thakur, Christopher C Butler, Karthik Ramasamy, Anjan Thakurta, David A Clifton, Lei Clifton

Blood Adv bloodadvances.2025016120.

https://doi.org/10.1182/bloodadvances.2025016120

Published: 2025

Includes: Supplemental data

Journal Articles

BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma

Katja Gutmair, Diego Villa, Nicholas Cunningham, Elisabeth Silkenstedt, Lisa Rimsza, Colleen Ramsower, David W. Scott, Alina S. Gerrie, Hanneke C. Kluin-Nelemans, Martin Dreyling, Eva Hoster

Blood Adv (2025) 9 (9): 2302–2306.

https://doi.org/10.1182/bloodadvances.2024015292

Published: 2025

Includes: Supplemental data

Journal Articles

Presentation of CXCL12γ by heparan sulfate proteoglycans activates CXCR4 without desensitization in normal and malignant B cells

Hildo C. Lantermans, Fangxue Ma, Annemieke Kuil, Martin F. M. de Rooij, Nick D. Bergkamp, Werner van der Meer, Jaap D. van Buul, Martine J. Smit, Marie José Kersten, Marcel Spaargaren, Steven T. Pals

Blood Adv (2025) 9 (9): 2307–2320.

https://doi.org/10.1182/bloodadvances.2024014396

Published: 2025

Includes: Supplemental data

Journal Articles

Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study

Elizabeth H. Phillips, Nicholas Counsell, Tim Illidge, Marc Andre, Igor Aurer, Valeria Fiaccadori, Catherine Fortpied, Anouk Neven, Massimo Federico, Sally F. Barrington, John Raemaekers, John Radford

Blood Adv (2025) 9 (9): 2266–2274.

https://doi.org/10.1182/bloodadvances.2024015140

Published: 2025

Includes: Supplemental data

Journal Articles

Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review

Luke Wang, Eliza Chung, Cameron Wellard, Allison Barraclough, Belinda A. Campbell, Geoffrey Chong, Pietro R. Di Ciaccio, Gareth P. Gregory, Greg Hapgood, Anna M. Johnston, Constantine Tam, Stephen Opat, Erica M. Wood, Zoe K. McQuilten, Eliza A. Hawkes

Blood Adv (2025) 9 (9): 2275–2284.

https://doi.org/10.1182/bloodadvances.2024015072

Published: 2025

Includes: Supplemental data

Journal Articles

TRANSCAR: Real-World outcomes of CD19CAR T Cell Therapy in relapsed/refractory transformed indolent lymphomas

Pierre Stephan, Roberta Di Blasi, Louise Roulin, Jean Galtier, Julien Calvani, Veronique Meignin, Marie Donzel, Alexandra Traverse-Glehen, Elsa Poullot, Marie-Cécile Parrens, Vivien Dupont, Alexandra Marquet, Steven Le Gouill, Roch Houot, Francois-Xavier Gros, François Lemonnier, Emmanuel Bachy, Catherine Thieblemont, Pierre Sesques

Blood Adv bloodadvances.2025015834.

https://doi.org/10.1182/bloodadvances.2025015834

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting Siglec-Sialic Acid Checkpoint to Reverse Immune Dysfunction Mediated by Plasmacytoid Dendritic Cells in Myeloma

Arghya Ray, Leutz Buon, Xueping Wan, Ting Du, Yan Song, Sindhu C Pillai, Md Abu Musa, Teng Fang, Minxing Wang, Kenneth C. Anderson

Blood Adv bloodadvances.2025015980.

https://doi.org/10.1182/bloodadvances.2025015980

Published: 2025

Includes: Supplemental data

Journal Articles

Lymphoma B cells remodel bone marrow stromal cells into extracellular matrix-producing cancer-associated fibroblasts

Elise Dessauge, Baptiste Brauge, Simon Léonard, Alicia Beyou, Camille Laurent, Valentin Isen, Nicolas laurent luc Barbier, Celine Monvoisin, Thomas Lejeune, Jérôme Destin, Florence Jouan, Judikael Saout, Francisco Llamas Gutierrez, Franck Morschhauser, Sandrine Roulland, David Roulois, Frederic Mourcin, Karin Tarte

Blood Adv bloodadvances.2024015616.

https://doi.org/10.1182/bloodadvances.2024015616

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 1 trial of durvalumab (anti–PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma

Christiane Querfeld, Joycelynne Palmer, Zhen Han, Xiwei Wu, Yate-Ching Yuan, Min-Hsuan Chen, Chingyu Su, Ni-Chun Tsai, D. Lynne Smith, Samantha N. Hammond, Liliana Crisan, Joo Y. Song, Raju Pillai, Steven T. Rosen, Jasmine Zain

Blood Adv (2025) 9 (9): 2247–2260.

https://doi.org/10.1182/bloodadvances.2024014655

Published: 2025

Includes: Supplemental data

Journal Articles

Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma

Blood Adv (2025) 9 (9): 2232–2246.

https://doi.org/10.1182/bloodadvances.2024015577

Published: 2025

Includes: Supplemental data

Journal Articles

High rate of complete responses induced by platinum-based regimen with BTK inhibitors in Richter's Syndrome

Georgios Pongas, Maryam Alasfour, Daniel P Cassidy, Juan Pablo Alderuccio, Joseph D. Rosenblatt, Izidore S Lossos

Blood Adv bloodadvances.2025015913.

https://doi.org/10.1182/bloodadvances.2025015913

Published: 2025

Journal Articles

TP53 mutations are associated with CD19 − relapse and inferior outcomes after blinatumomab in adults with ALL

Blood Adv (2025) 9 (9): 2159–2172.

https://doi.org/10.1182/bloodadvances.2024014986

Published: 2025

Includes: Supplemental data

Journal Articles

Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma

Blood Adv (2025) 9 (9): 2122–2135.

https://doi.org/10.1182/bloodadvances.2024015161

Published: 2025

Includes: Supplemental data

Journal Articles

Statin use and survival in SLL/CLL treated with ibrutinib: Pooled analysis of four randomized controlled trials

Ahmad Y Abuhelwa, Sara A Almansour, Jennifer R. Brown, Humaid O Al-Shamsi, Ziad Abuhelwa, Zelal Kharaba, Yasser Bustanji, Mohammad H Semreen, Salma M. Ali, Ahmad Alhuraiji, Ross A McKinnon, Michael J Sorich, Karem H Alzoubi, Ashley M Hopkins

Blood Adv bloodadvances.2024015287.

https://doi.org/10.1182/bloodadvances.2024015287

Published: 2025

Includes: Supplemental data

Journal Articles

Genetic deregulation of REL in germinal center B-cells induces generation of a pool of lymphoma precursor cells

Léa Prévaud, Karima Ferhat, Dilara Sensoy, Ophélie Téteau, Tiffany Marchiol, Quentin Lemasson, Catherine Ouk-Martin, Claire Carrion, Michel Cogné, Jean Feuillard, Christelle Vincent-Fabert, Nathalie Faumont

Blood Adv bloodadvances.2023012166.

https://doi.org/10.1182/bloodadvances.2023012166

Published: 2025

Includes: Supplemental data

Journal Articles

Feasibility and favorable responses after investigational CAR T-cell therapy for relapsed and refractory infant ALL

Colleen Annesley, Adam Lamble, Corinne Summers, Michael A. Pulsipher, Alan S. Wayne, Julie Rivers, Wenjun Huang, Ashley Wilson, Qian Vicky Wu, Kristy Seidel, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, Michael Jensen, Rebecca Gardner

Blood Adv (2025) 9 (9): 2068–2078.

https://doi.org/10.1182/bloodadvances.2024012638

Published: 2025

Includes: Supplemental data

Journal Articles

Supernumerary ring chromosome 1 syndrome leads to fusion-driven B-cell acute lymphoblastic leukemia in monozygotic twins

Jesús Gutiérrez-Abril, Gunes Gundem, Elise Fiala, Konstantinos Liosis, Noushin Farnoud, Dan Leongamornlert, Anu Amallraja, Juan E. Arango-Ossa, Dylan Domenico, Max Levine, Juan S. Medina-Martínez, Emily Stockfisch, Daoqi You, Mike Walsh, Sylwia Jasinski, Andrew L. Kung, Neerav N. Shukla, William L. Carroll, Elli Papaemmanuil

Blood Adv (2025) 9 (9): 2063–2067.

https://doi.org/10.1182/bloodadvances.2024014869

Published: 2025

Includes: Supplemental data

Journal Articles

Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study

Beatrice Casadei, Lisa Argnani, Alessandro Broccoli, Martina Cantelli, Gabriele Gugliotta, Marianna Gentilini, Matteo Carella, Vittorio Stefoni, Cinzia Pellegrini, Nicole Fabbri, Giulia Gabrielli, Camilla Mazzoni, Pierluca Maglio, Gianmarco Bagnato, Pier Luigi Zinzani

Blood Adv (2025) 9 (9): 2044–2047.

https://doi.org/10.1182/bloodadvances.2024015581

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

GVHD in the era of checkpoint inhibition in Hodgkin lymphoma

Molecular profiling of primary renal Marginal Zone Lymphoma reveals overlapping features with extranodal Marginal Zone Lymphoma

Dysregulated immune proteins in plasma in the UK Biobank predict Multiple Myeloma 12 years before clinical diagnosis

BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma

Presentation of CXCL12γ by heparan sulfate proteoglycans activates CXCR4 without desensitization in normal and malignant B cells

Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study

Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review

TRANSCAR: Real-World outcomes of CD19CAR T Cell Therapy in relapsed/refractory transformed indolent lymphomas

Targeting Siglec-Sialic Acid Checkpoint to Reverse Immune Dysfunction Mediated by Plasmacytoid Dendritic Cells in Myeloma

Lymphoma B cells remodel bone marrow stromal cells into extracellular matrix-producing cancer-associated fibroblasts

Phase 1 trial of durvalumab (anti–PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma

Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma

High rate of complete responses induced by platinum-based regimen with BTK inhibitors in Richter's Syndrome

TP53 mutations are associated with CD19 − relapse and inferior outcomes after blinatumomab in adults with ALL

Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma

Statin use and survival in SLL/CLL treated with ibrutinib: Pooled analysis of four randomized controlled trials

Genetic deregulation of REL in germinal center B-cells induces generation of a pool of lymphoma precursor cells

Feasibility and favorable responses after investigational CAR T-cell therapy for relapsed and refractory infant ALL

Supernumerary ring chromosome 1 syndrome leads to fusion-driven B-cell acute lymphoblastic leukemia in monozygotic twins

Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only